The most common cause of anemia is deficiency of iron. A number of intravenous iron formulations have been developed. One of the recent addition to the list of available parenteral iron preparation is Ferric carboxymaltose. It is still relatively new in India and is yet to find its place in India for routine use. One clinically important but less common adverse reaction of Ferric carboxymaltose is increase in the Alanine Aminotransferase (ALT) as well as Aspartate Aminotransferase (AST) levels. In our patient we encountered significant increase in the ALT and AST levels after receiving Ferric carboxymaltose therapy.